Andrographis Paniculata Drug Interactions: Key Study Insights
Quick Summary: This lab study tested Synacinn™, a herbal supplement blend including Andrographis paniculata (a plant used for immune and blood sugar support), to see if it interferes with common medications. At high doses, the full blend strongly blocked key liver enzymes that break down drugs, but Andrographis' main compound (andrographolide) showed little to no interference—curcumin from another herb was the main culprit. This suggests potential risks when mixing the blend with diabetes meds or other drugs, but isolated Andrographis may be safer.
What the Research Found
Researchers checked how Synacinn™—made from five herbs like Andrographis paniculata, turmeric (curcumin source), and cinnamon—affects cytochrome P450 enzymes. These are liver proteins that process many prescription drugs, like those for diabetes, pain, or cholesterol.
- The full Synacinn™ blend completely (100%) blocked eight key enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and two forms of CYP3A4) at a high test dose of 5000 µg/ml.
- The strength of this block varied: It took as little as 0.23 mg/ml to half-block CYP1A2, up to 1.23 mg/ml for CYP2C19.
- When testing individual plant compounds (biomarkers), most—including andrographolide from Andrographis—had no, low, or moderate effects on the enzymes.
- Only curcumin (from Curcuma xanthorrhiza) strongly blocked three enzymes: 91% for CYP2C8, 81% for CYP2C9, and 72% for CYP2C19 at a low test dose of 10 µM.
- Bottom line: The blend's interference comes mostly from curcumin, not Andrographis, so users should time it away from drugs processed by these enzymes.
This means Synacinn™ could make some meds build up in your body, raising side effect risks, but Andrographis alone likely doesn't contribute much.
Study Details
- Who was studied: No people or animals—this was a lab test using human liver cell extracts (microsomes) to mimic how the body processes drugs. It focused on the supplement's effects in a controlled setup.
- How long: The tests were one-time lab experiments, not over days or weeks—no ongoing monitoring was needed.
- What they took: Synacinn™ was tested at up to 5000 µg/ml (a lab concentration, not a real-world dose). Its plant compounds, like andrographolide from Andrographis, were tested at 10 µM. They used a tool called LC-MS/MS to measure enzyme activity with "probe" chemicals that mimic drug breakdown.
The study aimed to spot herb-drug interactions for Synacinn™, often used as a diabetes supplement alongside meds.
What This Means For You
If you're taking Andrographis paniculata for colds, inflammation, or blood sugar help, this study is reassuring: Its key ingredient (andrographolide) doesn't strongly interfere with most common drugs. But if you're using a blend like Synacinn™ (for diabetes support), be cautious—it might slow down how your body clears meds like statins, antidepressants, or blood thinners, potentially causing stronger effects or side effects.
- Practical tip: Space out the supplement and your meds by 2-4 hours, as suggested. Always chat with your doctor or pharmacist before combining herbs with prescriptions, especially if you have diabetes or take multiple drugs.
- For everyday users: Isolated Andrographis supplements seem low-risk for interactions based on this, but the full blend raises flags—stick to trusted sources and monitor for unusual symptoms like dizziness or fatigue.
Study Limitations
This was all done in a lab dish, not in real people, so it doesn't prove what happens in your body after taking the supplement orally—factors like absorption and real blood levels weren't tested. The high doses used (like 5000 µg/ml) are way above what you'd get from a pill, so everyday use might not cause the same strong effects. It only looked at blocking (inhibition), not if the herbs could boost enzyme activity over time. Plus, it tested single compounds separately, but the real blend might interact differently. More human studies are needed to confirm safety.
Technical Analysis Details
Key Findings
Synacinn™ (a polyherbal supplement containing Andrographis paniculata standardized to andrographolide) demonstrated 100% inhibition of all tested cytochrome P450 enzymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4) at 5000 µg/ml. IC50 values ranged from 0.23 mg/ml (CYP1A2) to 1.23 mg/ml (CYP2C19). Crucially, individual biomarkers—including andrographolide (from A. paniculata)—showed no, minimal, or moderate inhibition across all enzymes. Only curcumin significantly inhibited CYP2C8 (91%), CYP2C9 (81%), and CYP2C19 (72%) at 10 µM. The study concluded that curcumin—not andrographolide—is the primary driver of Synacinn™'s CYP inhibition, suggesting potential herb-drug interactions with medications metabolized by these enzymes.
Study Design
This in vitro observational study used human liver microsomes and LC-MS/MS to assess CYP450 inhibition. It tested Synacinn™ and its individual phytochemical biomarkers (rosmarinic acid, gallic acid, curcumin, catechin, andrographolide) against eight CYP enzymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4-midazolam, 3A4-testosterone). No human/animal subjects were involved; experiments were conducted in biochemical assay systems. Duration and sample size are not applicable to this methodology.
Dosage & Administration
Synacinn™ was tested at concentrations up to 5000 µg/ml. Individual biomarkers were evaluated at 10 µM. Administration details are irrelevant as this was an in vitro microsomal assay, not a clinical trial involving oral intake.
Results & Efficacy
Synacinn™ showed complete inhibition (100%) of all eight CYP enzymes at 5000 µg/ml. IC50 values were:
- CYP1A2: 0.23 mg/ml
- CYP2B6: 0.60 mg/ml
- CYP2C8: 0.47 mg/ml
- CYP2C9: 0.78 mg/ml
- CYP2C19: 1.23 mg/ml
- CYP2D6: 0.99 mg/ml
- CYP3A4 (midazolam): 1.01 mg/ml
- CYP3A4 (testosterone): 0.91 mg/ml
Andrographolide (the A. paniculata biomarker) exhibited no significant inhibition of any CYP enzyme. Curcumin was the sole biomarker with strong inhibitory effects (CYP2C8: 91%, CYP2C9: 81%, CYP2C19: 72% at 10 µM). Statistical significance metrics (p-values, confidence intervals) were not provided in the summary.
Limitations
The study is limited by its purely in vitro design, using supraphysiological concentrations (5000 µg/ml far exceeds expected human plasma levels). It did not assess time-dependent inhibition, enzyme induction, or metabolite contributions. No kinetic analysis (Ki values) was performed. Results cannot directly predict in vivo interactions in humans, as absorption, distribution, and metabolism were not modeled. The focus on single biomarkers ignores potential synergistic effects within the full herbal mixture.
Clinical Relevance
Supplement users should be aware that Synacinn™—not isolated Andrographis paniculata—poses a high theoretical risk for herb-drug interactions with medications metabolized by CYP enzymes (e.g., warfarin, antidepressants, statins). Since andrographolide showed negligible inhibition, A. paniculata alone may have lower interaction risk. However, this study supports the recommendation to separate Synacinn™ intake from conventional drugs by several hours. Patients on narrow-therapeutic-index drugs should consult healthcare providers before using this specific polyherbal product. Isolated A. paniculata supplements may not carry the same interaction risk based on these data.
Original Study Reference
Evaluation of Herb-Drug Interaction of Synacinn™ and Individual Biomarker through Cytochrome 450 Inhibition Assay.
Source: PubMed
Published: 2018
📄 Read Full Study (PMID: 29542427)